
Opinion|Videos|March 1, 2025
Current and Emerging Treatment Landscape of mHSPC
Jack Andrews MD; Eugene Cone, MD; and Arash Rezazadeh, MD, discuss how metastatic hormone-sensitive prostate cancer presents clinically, explore current treatment standards including combination therapies, evaluate emerging data from the ARANOTE trial on darolutamide efficacy, consider quality of life factors in treatment selection, and examine how novel therapeutic approaches may reshape future care pathways.
Advertisement
Episodes in this series

Timecodes
1:54 mHSPC and Imaging
4:57 Current SOC in mHSPC
10:15 Choosing Therapy in mHSPC
18:51 ARANOTE Trial in mHSPC
21:15 Experience With ARI
27:08 Emerging mHSPC Treatments
32:51 ARANOTE Subgroup Analysis
35:31 Future Outlook for mHSPC
Advertisement
Advertisement
Advertisement
Trending on Urology Times
1
Managing BPH Before Prostate Radiotherapy: Options Compared
2
Patient Selection and Partnership in Prostate Radiotherapy Spacing
3
The role of diet and lifestyle in prostate cancer care, with Lorelei A. Mucci, ScD, MPH
4
Alternative BCG strains may help address ongoing supply challenges in NMIBC
5










